Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1969-12-1
pubmed:abstractText
1. In cats anaesthetized with pentobarbitone sodium, hexobendine (0.25 mg/kg) markedly increased myocardial blood flow (measured using a heat clearance technique) and usually decreased myocardial metabolic heat production, without influencing cardiac contractility or systemic arterial blood pressure. These effects lasted for about 45 min.2. Larger doses (0.5 and 1.0 mg/kg) decreased systemic arterial blood pressure and the rate of rise of the left ventricular pressure pulse (dp/dt), although left ventricular end-diastolic pressure was usually increased. This is indicative of a decrease in myocardial contractility.3. In a concentration of 5 x 10(-6) g/ml., hexobendine protected isolated rabbit atria against the decrease in contractility that follows the removal of oxygen.4. Hexobendine did not antagonize the systemic and myocardial effects of infusions of adrenaline and noradrenaline, nor (except in concentrations of 10(-5) g/ml.) the increase in contractility induced by these catecholamines on isolated rabbit atria.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-13175107, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-13346631, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-13708086, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-13740337, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-13817738, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-14126055, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-14302359, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-14305301, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-14343467, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-14346986, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-14399194, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-16783907, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-4307053, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-4382675, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-5232123, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-5755840, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-6014577, http://linkedlifedata.com/resource/pubmed/commentcorrection/5343351-6050495
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
272-82
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1969
pubmed:articleTitle
Studies on the mode of action of hexobendine, a prospective anti-anginal drug.
pubmed:publicationType
Journal Article, In Vitro